

Table e-1. Ocrelizumab induced changes in leukocyte blood subsets (n=53*).

	<i>Absolute numbers (cells/μL)</i>			<i>Percentages [Subset]</i>		
	0M	6M	<i>p</i>	0M	6M	<i>p</i>
Lymph	1908 (1554-2309)	1745 (1312-1984)	<i>ns</i>			
CD19	232 (148-354)	9.1 (1.9-41)	<0.0001			
TransB [CD19]	4.0 (2.1-7.5)	2.2 (0.1-25)	<i>ns</i>	1.2 (0.5-2.9)	14.3 (5.6-27.5)	<0.0001
NaïveB [CD19]	128 (89-194)	0.5 (0.1-6.1)	<0.0001	36.8 (15.2-52.2)	7.7 (3.7-13.2)	<0.0001
MemB [CD19]	47 (29-121)	2.0 (0.7-4.4)	<0.0001	24.9 (14.0-40.9)	38.1 (10.1-51.2)	<i>ns</i>
PB [CD19]	0.5 (0.2-1.0)	0.3 (0.1-0.7)	<i>ns</i>	0.2 (0.07-0.5)	4.0 (1.2-10.4)	<0.0001
CD3	1290 (1008-1642)	1491 (983-1778)	<i>ns</i>			
CD20* [CD3]	30 (11-51)	8.4 (3.6-15)	<0.0001	2.5 (0.7-3.9)	0.5 (0.3-1.2)	<0.0001
CD4	863 (634-1204)	968 (719-1387)	<i>ns</i>			
Treg [CD4]	91 (61-121)	103 (78-136)	<i>ns</i>	10.6 (7.3-13.2)	11.0 (9.3-14.4)	<i>ns</i>
Naïve [CD4]	415 (248-694)	518 (358-775)	<i>ns</i>	52.2 (35.1-63.8)	54.5 (42.0-66.4)	<i>ns</i>
CM [CD4]	250 (166-340)	271 (193-353)	<i>ns</i>	26.8 (21.1-38.1)	28.7 (20.7-34.6)	<i>ns</i>
EM [CD4]	121 (60-205)	127 (72-191)	<i>ns</i>	15.4 (7.3-22.6)	11.8 (8.2-18.5)	<i>ns</i>
TD [CD4]	23 (14-38)	26 (11-46)	<i>ns</i>	2.9 (1.6-5.1)	2.6 (1.3-4.1)	0.0008
CD8	272 (191-470)	270 (192-438)	<i>ns</i>			
Naïve [CD8]	77 (40-121)	76 (56-128)	<i>ns</i>	28.7 (17.8-43.3)	33.4 (22.4-50.0)	0.01
CM [CD8]	17 (8.8-33)	16 (7.6-31)	<i>ns</i>	7.4 (3.5-10.5)	6.1 (3.6-11.1)	<i>ns</i>
EM [CD8]	85 (38-114)	68 (32-95)	<i>ns</i>	24.7 (17.4-37.9)	22.0 (13.8-31.0)	0.001
TD [CD8]	90 (49-195)	76 (31-165)	<i>ns</i>	32.1 (22.1-42.6)	29.0 (20.4-42.1)	<i>ns</i>
CD56	412 (256-582)	302 (235-520)	<i>ns</i>			
NKT [CD56]	92 (53-175)	90 (58-158)	<i>ns</i>	28.9 (16.5-42.7)	34.5 (19.9-40.8)	<i>ns</i>
CD56 ^{di} [CD56]	263 (170-392)	198 (138-306)	<i>ns</i>	66.4 (52.9-78.9)	61.7 (53.8-77.6)	<i>ns</i>
CD56 ^{br} [CD56]	15 (8.6-19)	10 (6.0-16)	0.005	3.1 (2.0-6.2)	2.9 (1.9-5.0)	<i>ns</i>
CD14	401 (260-527)	480 (318-621)	0.002			
PDL1 [CD14]	40 (21-72)	52 (20-94)	<i>ns</i>	43.0 (25.5-57.6)	38.4 (26.3-53.8)	<i>ns</i>

Footnote: Results are shown as Median (25-75% IQR). Absolute numbers are displayed as cells/ μ L. Percentages are referred to the subset included into square brackets []. P values were corrected by using Bonferroni test. 0M, 0 Months (pre-ocrelizumab treatment); 6M, 6 Months of ocrelizumab treatment; br, bright; CM, Central Memory;

di, dim; EM, Effector Memory; Lymph, lymphocytes; MemB, Memory B cells; NKT, Natural Killer T cells; ns, non-significant; PB, Plasmablasts; TD, Terminally differentiated; TransB, Transitional B cells; Treg, regulatory T cells. *CD20+ T cells were analyzed only in 39 patients of our cohort.